Nektar Therapeutics (NASDAQ:NKTR – Get Rating) Director Myriam Curet sold 4,198 shares of the stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $3.16, for a total value of $13,265.68. Following the completion of the sale, the director now directly owns 31,777 shares of the company's stock, valued at approximately $100,415.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $3.08 on Tuesday. The business has a 50 day simple moving average of $4.10 and a 200 day simple moving average of $4.26. Nektar Therapeutics has a one year low of $3.02 and a one year high of $19.37. The stock has a market capitalization of $577.21 million, a P/E ratio of -1.09 and a beta of 1.16.

Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.16. Nektar Therapeutics had a negative return on equity of 82.40% and a negative net margin of 544.77%. The business had revenue of $21.59 million during the quarter, compared to analysts' expectations of $22.75 million. During the same quarter last year, the firm posted ($0.69) earnings per share. The firm's revenue was down 23.8% on a year-over-year basis. Equities analysts expect that Nektar Therapeutics will post -2.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Calton & Associates Inc. bought a new position in Nektar Therapeutics in the first quarter worth approximately $55,000. Vantage Consulting Group Inc bought a new position in Nektar Therapeutics in the second quarter worth approximately $41,000. Arete Wealth Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $59,000. Finally, Halbert Hargrove Global Advisors LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $61,000. Institutional investors own 96.99% of the company's stock.

Nektar Therapeutics Company Profile

(Get Rating)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

See Also

• Get a free copy of the StockNews.com research report on Nektar Therapeutics (NKTR)
• MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
• MO Money: Why Altria Group Stock is Rallying
• Is the Market Overreacting with Shopify Stock?
• Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Three Consumer Stocks That Could Outperform In Q4

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.